Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenido archivado el 2024-05-29

Molecular signatures as diagnostic and therapeutic targets for disseminated epithelial malignancies

Objetivo

Disseminated tumour cells (DTC) occur at very low numbers and can be detected using sensitive immunostaining and PCR methods. However, sensitivity and in particular specificity of this approach need to be improved. Combining the expertise of 11 academic pa rtners with long-term expertise in micrometastasis research the DISCOUNT-project will establish an improved platform for DTC detection with an increased sensitivity and - in particular - with a largely improved specificity. Besides DTC detection also analy sis of circulating tumour DNA and RNA, and expression profiling of tumours are being explored for assessment of minimal disease. We will focus on epithelial tumours as the most common types of solid tumours in the EU, investigating the carcinoma types that display different modes of metastatic spread. Dissemination into regional lymph nodes will be analyzed as well as haematogeneous dissemination of DTC via the blood circulation, using bone marrow as an important indicator organ to which epithelial tumour c ells home. Using genomics-based approaches, novel diagnostic target molecules will be identified and validated in functional models. We will complement immunocytochemical DTC detection by additional genotypic and phenotypic markers relevant for metastatic progression. To further increase diagnostic precision we will analyze whether this improved platform can be combined with analysis of tumour characteristics that were revaled by the microarray analysis, and with evaluation of circulating tumour-associated DNA or RNA. Besides the focus on improvement of DTC-based diagnostic platforms, it is important to realize that these cells are the target cells for adjuvant chemotherapy and radiotherapy. In innovative DTC models, the efficacy of DTC treatment will there-fore be analyzed and potential improvements studied. The translation of scientific knowledge into commerical products will be ensured by 3 SMEs with unique technological capabilities.

Ámbito científico (EuroSciVoc)

CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véase: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

Para utilizar esta función, debe iniciar sesión o registrarse

Convocatoria de propuestas

FP6-2004-LIFESCIHEALTH-5
Consulte otros proyectos de esta convocatoria

Régimen de financiación

IP - Integrated Project

Coordinador

UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF
Aportación de la UE
Sin datos

Participantes (13)